Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Kestra Medical Technologies (KMTS) Preferred Shares Issued (2024)

Kestra Medical Technologies (KMTS) has disclosed Preferred Shares Issued for 1 consecutive years, with $103.4 million as the latest value for Q3 2024.

  • Quarterly Preferred Shares Issued changed N/A to $103.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $103.4 million through Apr 2025, changed N/A year-over-year, with the annual reading at $103.4 million for FY2025, 37.87% up from the prior year.
  • Preferred Shares Issued for Q3 2024 was $103.4 million at Kestra Medical Technologies, up from $12.5 million in the prior quarter.
  • The five-year high for Preferred Shares Issued was $103.4 million in Q3 2024, with the low at $12.5 million in Q2 2024.